Literature DB >> 413839

Inhibition of platelet prostaglandin synthetase by oral aspirin.

J W Burch, N Stanford, P W Majerus.   

Abstract

Aspirin inhibits platelet function by permanently acetylating the cyclooxygenase that forms prostaglandins. We determined the sensitivity of platelets to aspirin in normal subjects by measuring [3H-acetyl]aspirin-susceptible cyclooxygenase in washed platelets obtained at various times after aspirin ingestion. A single 325-mg aspirin dose inactivated 89% of platelet cyclooxygenase. The inhibition persisted for 2 days suggesting that oral aspirin also inactivated megakaryocyte cyclooxygenase. Thereafter, active enzyme returned with a time-course reflecting platelet turnover (life-span 8.2+/-2 days). Single doses of 20-650 mg aspirin resulted in 34- greater than 95% inhibition after 24 h. Daily doses of 20-325 mg aspirin for brief periods produced 61- greater than 95% inactivation when measured 24 h after cessation of the drug. Platelet cyclooxygenase is more sensitive to inactivation by aspirin than enzyme in sheep seminal vesicles.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 413839      PMCID: PMC372541          DOI: 10.1172/JCI108941

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  34 in total

1.  Effect of aspirin on prostaglandin synthesis by human platelets.

Authors:  E Jafari; A Saleem; B S Shaikh; L M Demers
Journal:  Prostaglandins       Date:  1976-11

2.  Effect of aspirin on human seminal prostaglandins.

Authors:  J G Collier; R J Flower
Journal:  Lancet       Date:  1971-10-16       Impact factor: 79.321

3.  Effects of salicylates on human platelets.

Authors:  J R O'Brien
Journal:  Lancet       Date:  1968-04-13       Impact factor: 79.321

4.  Aspirin selectively inhibits prostaglandin production in human platelets.

Authors:  J B Smith; A L Willis
Journal:  Nat New Biol       Date:  1971-06-23

5.  Evidence that the spleen retains the youngest and hemostatically most effective platelets.

Authors:  N R Shulman; S P Watkins; S B Itscoitz; A B Students
Journal:  Trans Assoc Am Physicians       Date:  1968

Review 6.  The Gordon Wilson lecture: function of blood platelets and their role in thrombosis.

Authors:  J F Mustard
Journal:  Trans Am Clin Climatol Assoc       Date:  1976

7.  Isolation of human platelets and platelet surface membranes.

Authors:  N L Baenziger; P W Majerus
Journal:  Methods Enzymol       Date:  1974       Impact factor: 1.600

8.  Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac ateries and inhibits platelet aggregation.

Authors:  S Bunting; R Gryglewski; S Moncada; J R Vane
Journal:  Prostaglandins       Date:  1976-12

Review 9.  Are agents affecting platelet functions clinically useful?

Authors:  M Verstraete
Journal:  Am J Med       Date:  1976-12       Impact factor: 4.965

10.  Physiological role of an endoperoxide in human platelets: hemostatic defect due to platelet cyclo-oxygenase deficiency.

Authors:  C Malmsten; M Hamberg; J Svensson; B Samuelsson
Journal:  Proc Natl Acad Sci U S A       Date:  1975-04       Impact factor: 11.205

View more
  80 in total

Review 1.  Drugs used in secondary prevention after myocardial infarction: case presentation.

Authors:  S Maxwell; W S Waring
Journal:  Br J Clin Pharmacol       Date:  2000-11       Impact factor: 4.335

2.  A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin.

Authors:  M Ouellet; D Riendeau; M D Percival
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

3.  Sensitivity of fatty acid cyclooxygenase from human aorta to acetylation by aspirin.

Authors:  J W Burch; N L Baenziger; N Stanford; P W Majerus
Journal:  Proc Natl Acad Sci U S A       Date:  1978-10       Impact factor: 11.205

4.  Easy bruising in women.

Authors:  B Garvey
Journal:  Can Fam Physician       Date:  1984-09       Impact factor: 3.275

Review 5.  Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  John W Eikelboom; Jack Hirsh; Frederick A Spencer; Trevor P Baglin; Jeffrey I Weitz
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

6.  Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects.

Authors:  P Patrignani; P Filabozzi; C Patrono
Journal:  J Clin Invest       Date:  1982-06       Impact factor: 14.808

Review 7.  Zomepirac: a review of its pharmacological properties and analgesic efficacy.

Authors:  P A Morley; R N Brogden; A A Carmine; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1982-04       Impact factor: 9.546

8.  Pharmacological interaction between nitroglycerin and aspirin after acute and chronic aspirin treatment of healthy subjects.

Authors:  E Rey; H D El-Assaf; M O Richard; S Weber; A Bourdon; G Picard; G Olive
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

9.  Release of prostacyclin from the human pulmonary vascular bed in response to cholinergic stimulation.

Authors:  R Brandt; A Dembińska-Kieć; R Korbut; R J Gryglewski; J Nowak
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-01       Impact factor: 3.000

10.  Inhibition of platelet function by a controlled release acetylsalicylic acid formulation--single and chronic dosing studies.

Authors:  M S Roberts; L J McLeod; P A Cossum; J H Vial
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.